anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The participants' anthropometric parameters will be assessed both subjectively and objectively to calculate the data. Weight will be measured in kilograms using a weight machine, and height will be measured in inches using a measuring tape and converted into meters, respectively, to determine BMI. Using a measuring tape, the chest, abdomen, thigh, triceps, and supraillium are measured to determine the skin fold measurement, which determines the body fat percentage. Circumference measurements, such as those taken of the midthigh, biceps, waist, hips, and conicity index. The body mass index, conicity index, weight scale, and inch tape will be used for these measurements.

A common tool is the International Physical Activity Questionnaire (IPAQ). The seven-day IPAQ-SF is a self-administered, scientifically validated recall questionnaire for children ages 7 to 14. The quantity of time a child spends exercising during the
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs classified as CD20-directed cytolytic antibodies, including rituximab-containing products. HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA levels or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, i.e., increase in transaminase levels. In severe cases increase in bilirubin levels, liver failure, and death can occur.

Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with a rituximab-containing product. For patients who show evidence of prior hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before and/or during treatment with a rituximab-containing product. Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following RITUXAN HYCELA. HBV reactivation has been reported up to 24 months following completion of therapy containing rituximab. 

In patients who develop reactivation of HBV while on RITUXAN HYCELA, immediately discontinue treatment and any concomitant chemotherapy, and institute appropriate treatment. Insufficient data exist regarding the safety of resuming RITUXAN HYCELA treatment in patients who develop HBV reactivation. Resumption of RITUXAN HYCELA treatment in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing HBV.
The present invention deals with new radiopharmaceuticals for renal studies with ligands labelled with technetium- 99m. The ligands have the general formula: <IMAGE> where X and Y are NH, O or S and can be substituted in the N1 position by methyl, phenyl and phenethyl groups. The present invention indicates how to prepare these new compounds labelled with technetium-99m. In the case of the unsubstituted ligand and when X = Y = NH, the substance is biguanide. This ligand, when labelled with technetium-99m, is preferentially eliminated by the kidneys, having an elimination kinetics favourable to renal diagnostic studies. Tests in laboratory animals show that biguanide labelled with technetium-99m presents advantages from the standpoint of clinical practice and lower radiation dose than a currently used radiopharmaceutical, dimercaptosuccinic acid, DMSA.
The present inventors find that PEP-1-PON1 fusion proteins can protect dopaminergic neurons from oxidative stress in SH-SY5Y neuroblastoma cells and animal models of Parkinson′s disease. The PEP-1-PON1 fusion proteins are confirmed to be capable of easily moving into the SH-SY5Y neuroblastoma cells and substantia nigra of the brain. The PEP-1-PON1 fusion proteins can significantly suppress the generation of the reactive oxygen species induced by MPP+ and DNA fragmentation, thereby inducing the survival of SH-SY5Y cells consequently. The PEP-1-PON1 fusion proteins influence to the level of the pro-apoptotic mediator and the anti-self-apoptotic mediator to obtain the neuroprotective effects. Furthermore, TH antibodies and the immunohistochemical analysis data using the cresyl violet dye shows the PEP-1-PON1 fusion proteins can significantly protect the dopamine cells in the substantia nigra from the oxidative strees such as MPTP. Accordingly, the PEP-1-PON1 fusion proteins can be used for the prevention and treatment of Parkinson′s disease.
The invention relates to a component type freckle-removing beauty cream and a preparation method thereof, belonging to the technical field of freckle-removing beauty skin care products. The medicament is prepared from a component A and a component B, wherein the component A comprises hirudin, periostracum cicadae, periostracum Serpentis, kojic acid and other raw materials in certain parts by weight. The hirudin has effects of dilating skin capillary, improving dermal blood microcirculation, promoting melanocyte metabolism, and promoting absorption by skin cells. The periostracum Serpentis and periostracum Cicadae can accelerate metabolism of skin surface cell and exfoliation of epidermal macula, and promote generation of new skin, and have effects of enhancing skin elasticity and eliminating mottle. Kojic acid has effects of retaining water and increasing skin elasticity, and has good therapeutic effect on mottle such as freckle and pigmentation. Simple preparation method, quick effect for removing speckle, short treatment period, no damage to facial skin, low cost, and convenient application. Solves the problems that the existing chemical freckle-removing cosmetics damage skin, and the existing traditional Chinese medicine for treating the freckles has long period, slow curative effect, complex production process and high manufacturing cost.
BACKGROUND: The PI3K/Akt/mTOR pathway and autophagy are important physiological processes. But their roles in eCRSwNP remains controversial.
METHODS: In this study, we used the eCRSwNP mouse model, PI3K/Akt/mTOR pathway inhibitors, and autophagy inhibitors and activators to investigate the regulatory effects of the PI3K/Akt/mTOR pathway on autophagy, and their effects on eosinophilic inflammation, and tissue remodeling. The role of ILC2s in eCRSwNP was also studied, and the relationship between ILC2s and autophagy was preliminarily determined.
RESULTS: Our results show that eosinophilic inflammation in eCRSwNP mice could be inhibited by promoting the autophagy; otherwise, eosinophilic inflammation could be promoted. Meanwhile, inhibition of the PI3K/Akt/mTOR pathway can further promote autophagy and inhibit eosinophilic inflammation. Meanwhile, inhibiting the PI3K/Akt/mTOR pathway and promoting autophagy can reduce the number of ILC2s and the severity of tissue remodeling in the nasal polyps of eCRSwNP mice.
CONCLUSIONS: We conclude that the PI3K/Akt/mTOR pathway plays roles in eosinophilic inflammation and tissue remodeling of eCRSwNP, in part by regulating the level of autophagy. The downregulation of autophagy is a pathogenesis of eCRSwNP; therefore, the recovery of normal autophagy levels might be a new target for eCRSwNP therapy. Furthermore, autophagy might inhibit eosinophilic inflammation and tissue remodeling, in part by reducing the number of ILC2s.
This study reports on the development and pilot testing of an emotional support provision training intervention for interpersonal support providers to those with chronic illnesses. Using findings from a needs assessment in combination with existing theory and research, we created a training framework consisting of verbal person-centered message design, empathic listening, and communicated perspective-taking. Then, we recruited 282 individuals to participate in a pre-training questionnaire, the online training module, a post-training questionnaire, and a two-week post-training questionnaire. Outcome variables included emotional support knowledge, efficacy, and intentions, as well as general support efficacy, response efficacy, and quality. Repeated measures MANCOVA revealed significant increases from T1 to T2 for all variables of interest. These increases were sustained at T3 for emotional support knowledge and efficacy, and support provision response efficacy. Participants rated the training favorably and provided helpful suggestions for improvement. This study answers the call for more theoretically-grounded support interventions that not only assess theory in real-world settings, but also help people better their supportive communication skills.
Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity of ctDNA fragments in low tumor fraction (TF) settings and increase MRD sensitivity, we previously leveraged genome-wide mutational integration through plasma whole-genome sequencing (WGS). Here we now introduce MRD-EDGE, a machine-learning-guided WGS ctDNA single-nucleotide variant (SNV) and copy-number variant (CNV) detection platform designed to increase signal enrichment. MRD-EDGESNV uses deep learning and a ctDNA-specific feature space to increase SNV signal-to-noise enrichment in WGS by ~300× compared to previous WGS error suppression. MRD-EDGECNV also reduces the degree of aneuploidy needed for ultrasensitive CNV detection through WGS from 1 Gb to 200 Mb, vastly expanding its applicability within solid tumors. We harness the improved performance to identify MRD following surgery in multiple cancer types, track changes in TF in response to neoadjuvant immunotherapy in lung cancer and demonstrate ctDNA shedding in precancerous colorectal adenomas. Finally, the radical signal-to-noise enrichment in MRD-EDGESNV enables plasma-only (non-tumor-informed) disease monitoring in advanced melanoma and lung cancer, yielding clinically informative TF monitoring for patients on immune-checkpoint inhibition.
Sarcopenia is an age-related loss of muscle mass and function for which there is no approved pharmacological treatment. We tested direct efficacy by evaluating grip strength improvement in a sarcopenia mouse model rather than drug screening, which inhibits specific molecular mechanisms. Various physiological functions of ginseng berries are beneficial to the human body. The present study aimed to evaluate the efficacy and safety of steamed ginseng berry powder (SGBP). SGBP administration increased myotube diameter and suppressed the mRNA expression of sarcopenia-inducing molecules. SGBP also reduced the levels of inflammatory transcription factors and cytokines that are known to induce sarcopenia. Oral administration of SGBP improved muscle mass and physical performance in a mouse model of sarcopenia. In summary, our data suggest that SGBP is a novel therapeutic candidate for the amelioration of muscle weakness, including sarcopenia.
A small-group discussion (up to 6 participants) using patients with the same condition as the one selected for the clinical simulator will be held for participants allocated to the control group. These sessions will be led by a physician and have a maximum duration of up to 60 minutes.
<P>PROBLEM TO BE SOLVED: To produce a raw material for skin-permeable external preparation having high moisture retention and excellent skin permeation and for highly absorbable food by irradiating the collagen components and/or gelatin components obtained from fish skins or animal hides, e.g. a cow hide with radial rays to decompose them and reduce their molecular weight in no need of an organic solvent, a chemical, e.g. an additive or an enzyme.  <P>SOLUTION: The collagen components and/or gelatin components are irradiated with ionizing radiation, e.g. electron rays, gamma rays, proton rays, neutron rays and/or ultraviolet rays without use of a chemical solution and/or an enzyme. Thus, they are decomposed to a raw material with controlled molecular weight, that can be used as a skin-permeation external preparation having high moisture retention and high skin permeation or as a high absorption food.  <P>COPYRIGHT: (C)2003,JPO
UNLABELLED: Neonates face heightened susceptibility to drug toxicity, often exposed to off-label medications with dosages extrapolated from adult or pediatric studies. Premature infants in Neonatal Intensive Care Units (NICUs) are particularly at risk due to underdeveloped pharmacokinetics and exposure to multiple drugs. The study aimed to survey commonly used medications with a higher risk of ototoxicity and nephrotoxicity in Spanish and Italian neonatal units. A prospective cross-sectional study was conducted in Italian and Spanish neonatal units using a web-based survey with 43 questions. A modified Delphi method involved experts refining the survey through online consensus. Ethical approval was obtained, and responses were collected from January to July 2023. The survey covered various aspects, including drug-related ototoxic and nephrotoxic management, hearing screening, and therapeutic drug monitoring. Responses from 131 participants (35.9% from Spain and 64.1% from Italy) revealed awareness of drug toxicity risks. Varied practices were observed in hearing screening protocols, and a high prevalence of ototoxic and nephrotoxic drug use, including aminoglycosides (100%), vancomycin (70.2%), loop diuretics (63.4%), and ibuprofen (62.6%). Discrepancies existed in guideline availability and adherence, with differences between Italy and Spain in therapeutic drug monitoring practices.
CONCLUSIONS: The study underscores the need for clinical guidelines and uniform practices in managing ototoxic and nephrotoxic drugs in neonatal units. Awareness is high, but inconsistencies in practices indicate a necessity for standardization, including the implementation of therapeutic drug monitoring and the involvement of clinical pharmacologists. Addressing these issues is crucial for optimizing neonatal care in Southern Europe.
WHAT IS KNOWN: • Neonates in intensive care face a high risk of nephrotoxicity and ototoxicity from drugs like aminoglycosides, vancomycin, loop diuretics, and ibuprofen. • Therapeutic drug monitoring is key for managing these risks, optimizing dosing for efficacy and minimizing side effects.
WHAT IS NEW: • NICUs in Spain and Italy show high drug toxicity awareness but differ in ototoxic/nephrotoxic drug management. • Urgent need for standard guidelines and practices to address nephrotoxic risks from aminoglycosides, vancomycin, loop diuretics, and ibuprofen.
COSOPT PF is supplied in a foil pouch containing 15 low density polyethylene 0.2 mL single-use containers. 

NDC 17478-604-30, package of 60 single-use vials. 

NDC 17478-604-90, package of 180 single-use vials. 

Store COSOPT PF at 20° to 25°C (68° to 77°F). Do not freeze. 

Store in the original pouch. After the pouch is opened, store the remaining single-use containers in the foil pouch to protect from light. Write down the date you open the foil pouch in the space provided on the pouch. Discard any unused containers 15 days after first opening the pouch.
The present disclosure presents systems, devices and methods for administration of a therapeutic fluid to the body of a patient at a transient basal delivery profile, and enabling modification of the transient profile. Some embodiments include a user interface enabling input of one or more transient basal related parameters, and a processor having a basal programming application operating thereon. The basal programming application configured for determining a transient basal profile based on at least one or more transient basal related parameters. The transient basal profile comprises a plurality of phases and wherein each of the plurality of phases is characterized by a duration and at least one basal rate. In some embodiments, at least one of the plurality of phases includes either a basal overshot or a basal undershot. Some embodiments may also include a pump for dispensing the therapeutic fluid from a reservoir to the body of the patient.
Youth injured by violence is a major public health concern in Canada. It is the fourth cause of death and the leading reason for a youth to visit an emergency department. In Winnipeg 20% of youth who visit an emergency department with an injury due to violence have a second visit for a subsequent violent injury within the following year. This is consistent with studies in other jurisdictions that demonstrated that violent injury is a chronic condition.

Youth injured by violence have been shown to be in a reflective and receptive state of mind, rendering the emergency department setting appropriate for intervention. There are some hospital-based intervention programs for youth injured by violence in the U.S.; however, they have not been evaluated to assess repeat injury using a randomized control trial (RCT) and given the cost of this intervention, significant equipoise exists. It is essential to evaluate this intervention rigorously using RCT methodology. A pilot RCT is prudent prior to the main RCT.

The investigators propose a WrapAround Care model delivered by a support worker with lived experience with violence, supported by a social worker, an addictions and mental health counsellor, a family counsellor and links to multiple community supports. These community supports include partnerships with aboriginal and newcomer youth cultural programs as many youth impacted by violence are aboriginal and new immigrants to Canada. Support workers will be on call 24 hours a day, 7 days a week in order to start the intervention in the ED and take advantage of the "teachable moment".

This pilot study RCT will enroll 180 youth (aged 14 - 24) over one year (90 to each arm). The treatment arm will be the WrapAround care model initiated at the time of injury (i.e. in the emergency department). The control arm will be providing youth with a list of community programs and will be a waitlist control. The primary outcomes of the pilot study will evaluate evaluate recruitment, adherence, fidelity and safety of the intervention. The primary outcome for the main trial is repeat visit to any emergency department in Winnipeg for a subsequent injury due to interpersonal violence. This will be measured using a combination of administrative data and chart review to ensure high follow-up. The secondary outcomes include measurement of counts and severity of injury and housing and education changes. This intervention has been developed using a community based participatory research approach. Our team includes clinicians, nurses, social workers, community youth workers, former gang members, elders and researchers.
The invention discloses an application of a thladiantha dubia bunge root extract to the preparation of anti-inflammatory drugs or/and analgesics. Proved by experimental researches for a plurality of yThe invention discloses an application of a thladiantha dubia bunge root extract to the preparation of anti-inflammatory drugs or/and analgesics. Proved by experimental researches for a plurality of years, the thladiantha dubia bunge root extract has strong anti-inflammatory and analgesic actions, high efficiency and low toxicity, does not generate addiction, has no obvious side effect and has morears, the thladiantha dubia bunge root extract has strong anti-inflammatory and analgesic actions, high efficiency and low toxicity, does not generate addiction, has no obvious side effect and has more remarkable advantages than the prior central analgesics and antipyretic analgesics. The thladiantha dubia bunge root extract can be a thladiantha dubia bunge root water extract or a thladiantha dubie remarkable advantages than the prior central analgesics and antipyretic analgesics. The thladiantha dubia bunge root extract can be a thladiantha dubia bunge root water extract or a thladiantha dubia bunge root alcohol extract, the thladiantha dubia bunge root water extract is an extract obtained by routine techniques, such as crushing a thladiantha dubia bunge root dry product, adding water, dea bunge root alcohol extract, the thladiantha dubia bunge root water extract is an extract obtained by routine techniques, such as crushing a thladiantha dubia bunge root dry product, adding water, decocting, filtering, mixing filtrate, centrifugalizing supernatant fluid, decompressing, compressing, and the like, and the thladiantha dubia bunge root alcohol extract is an extract obtained by routincocting, filtering, mixing filtrate, centrifugalizing supernatant fluid, decompressing, compressing, and the like, and the thladiantha dubia bunge root alcohol extract is an extract obtained by routine techniques, such as crushing a thladiantha dubia bunge root dry product, refluxing with alcohol, extracting, filtering, mixing filtrate, centrifugalizing supernatant fluid, decompressing, compressine techniques, such as crushing a thladiantha dubia bunge root dry product, refluxing with alcohol, extracting, filtering, mixing filtrate, centrifugalizing supernatant fluid, decompressing, compressing, and the like. The two extracts can be directly used for preparing the anti-inflammatory drugs or/and the analgesics.g, and the like. The two extracts can be directly used for preparing the anti-inflammatory drugs or/and the analgesics.
This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, tolerability, and dose of daratumumab when administered in combination with various treatment regimens for different settings of multiple myeloma. The various treatment regimens to be combined with daratumumab in this study include Velcade-dexamethasone (VD), Velcade-melphalan-prednisone (VMP), Velcade-thalidomide-dexamethasone (VTD), pomalidomide-dexamethasone (Pom-dex), carfilzomib-dexamethasone (CFZ-dex) and carfilzomib-lenalidomide-dexamethasone (KRd). Approximately 250 patients (approximately 12 participants per VTD and VMP backbone treatment regimen, 6 for the VD regimen, up to 100 participants in the Pom-dex regimen, 80 for the CFZ-dex regimen \[10 participants will receive a single-dose of daratumumab and the remaining participants will receive a split-dose of daratumumab\], and up to 40 for the KRd regimen) will be enrolled in this study. The study will consist of screening, treatment, and follow-up phases. Treatment will extend to either the planned treatment duration for a maximum of 1 year (in Velcade-dexamethasone, Velcade-melphalan-prednisone, Velcade-thalidomide-dexamethasone regimens and KRd regimens), or in the Pom-dex and CFZ-dex regimens, until disease progression, unacceptable toxicity, or until the end of study. Follow-up will continue until the study ends (approximately 25 months after the last patient receives the first dose of daratumumab). Serial pharmacokinetic (study of what a drug does to the body) blood samples will be collected. Clinical efficacy outcomes and safety will be monitored throughout the study.